Advancing Novel Therapies
Torrey Bio's immunotherapies are designed to alter suppressive TME and create potent systemic antitumor immunity, and applicable to metastatic cancers in general
Development stages
Triple Negative Breast Cancer (TNBC)
Tumor microenvironment modulation
TBI-101 targets the immunosuppressive tumor microenvironment in metastatic breast cancer, restoring T-cell infiltration and anti-tumor immune response.
Colorectal Cancer (CRC)
Metastatic cascade disruption
Leveraging our foundational research in cancer progression, TBI-102 aims to interrupt the metastatic cascade in colorectal cancer before dissemination occurs.
Pipeline programs are in preclinical or early discovery stages. No clinical trials have been initiated. All data referenced is from preclinical research.
Interested in Collaboration?
We welcome partnerships with academic institutions, clinical research organizations, and industry collaborators who share our commitment to transforming cancer outcomes.